Md. Atikul Islam, Nishat Anjum, Md. Ataullah, Md. Abdul Muktadir Islam, Md. Nazmul Kayes, Muhammad Moniruzzaman and Md. Korban Ali
{"title":"生物相容性离子液体基水性胶束制剂,以提高难溶性药物的溶解度、稳定性和控释度","authors":"Md. Atikul Islam, Nishat Anjum, Md. Ataullah, Md. Abdul Muktadir Islam, Md. Nazmul Kayes, Muhammad Moniruzzaman and Md. Korban Ali","doi":"10.1039/D4NJ04364B","DOIUrl":null,"url":null,"abstract":"<p >The development of a universal carrier for sparingly soluble drugs (SSDs) remains a challenge to achieve an effective delivery system. To address this issue, surface active ionic liquid (SAIL)-based micellar systems have emerged as a prominent drug delivery carrier to increase the solubility of SSDs due to their exceptional physico-chemical properties. Herein, we report a new micellar formulation (MF) for SSDs (<em>e.g.</em>, naproxen, ibuprofen and rosuvastatin) comprising a biocompatible SAIL choline oleate ([Cho][Ole]). The solubility of naproxen, ibuprofen and rosuvastatin is 138, 237 and 158-fold greater, respectively, in the developed MF as compared to their solubility in water due to the presence of hydrogen-bonds, π–π interactions, and cation–π interactions between the drug and SAIL[Cho][Ole]. No indications of drug precipitation, color change, phase separation, or flocculation as well as no discernible change in the quantity of NAP were found indicating the exceptional stability of NAP-loaded MF. <em>In vitro</em> release studies of NAP-loaded MF were carried out using phosphate-buffered saline (PBS) with dialysis membranes, simulating the buffering conditions of physiological body fluids. This experiment showed a 50–60% burst release of NAP within the first 4 hours, with no substantial release after 12 hours, suggesting a sustained release of NAP. Furthermore, cytotoxicity studies of SAIL[Cho][Ole]-based MFs were conducted to evaluate the relative safety effect of the MF. The result was found that the LC<small><sub>50</sub></small> of SAIL[Cho][Ole] was 73.33 μg mL<small><sup>−1</sup></small> whereas that of the positive control was 0.159 μg mL<small><sup>−1</sup></small>, indicating the lower toxicity of SAIL[Cho][Ole]. These results clearly suggest that the SAIL[Cho][Ole]-based aqueous MFs represent a promising substitute to conventional surfactant-based MFs and can be used as a biocompatible carrier for SSDs as well as a valuable strategy for drug delivery systems at different therapeutic areas.</p>","PeriodicalId":95,"journal":{"name":"New Journal of Chemistry","volume":" 8","pages":" 3318-3327"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biocompatible ionic liquid-based aqueous micellar formulation to enhance solubility, stability and controlled release of sparingly soluble drugs†\",\"authors\":\"Md. Atikul Islam, Nishat Anjum, Md. Ataullah, Md. Abdul Muktadir Islam, Md. Nazmul Kayes, Muhammad Moniruzzaman and Md. Korban Ali\",\"doi\":\"10.1039/D4NJ04364B\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >The development of a universal carrier for sparingly soluble drugs (SSDs) remains a challenge to achieve an effective delivery system. To address this issue, surface active ionic liquid (SAIL)-based micellar systems have emerged as a prominent drug delivery carrier to increase the solubility of SSDs due to their exceptional physico-chemical properties. Herein, we report a new micellar formulation (MF) for SSDs (<em>e.g.</em>, naproxen, ibuprofen and rosuvastatin) comprising a biocompatible SAIL choline oleate ([Cho][Ole]). The solubility of naproxen, ibuprofen and rosuvastatin is 138, 237 and 158-fold greater, respectively, in the developed MF as compared to their solubility in water due to the presence of hydrogen-bonds, π–π interactions, and cation–π interactions between the drug and SAIL[Cho][Ole]. No indications of drug precipitation, color change, phase separation, or flocculation as well as no discernible change in the quantity of NAP were found indicating the exceptional stability of NAP-loaded MF. <em>In vitro</em> release studies of NAP-loaded MF were carried out using phosphate-buffered saline (PBS) with dialysis membranes, simulating the buffering conditions of physiological body fluids. This experiment showed a 50–60% burst release of NAP within the first 4 hours, with no substantial release after 12 hours, suggesting a sustained release of NAP. Furthermore, cytotoxicity studies of SAIL[Cho][Ole]-based MFs were conducted to evaluate the relative safety effect of the MF. The result was found that the LC<small><sub>50</sub></small> of SAIL[Cho][Ole] was 73.33 μg mL<small><sup>−1</sup></small> whereas that of the positive control was 0.159 μg mL<small><sup>−1</sup></small>, indicating the lower toxicity of SAIL[Cho][Ole]. These results clearly suggest that the SAIL[Cho][Ole]-based aqueous MFs represent a promising substitute to conventional surfactant-based MFs and can be used as a biocompatible carrier for SSDs as well as a valuable strategy for drug delivery systems at different therapeutic areas.</p>\",\"PeriodicalId\":95,\"journal\":{\"name\":\"New Journal of Chemistry\",\"volume\":\" 8\",\"pages\":\" 3318-3327\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-01-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"New Journal of Chemistry\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://pubs.rsc.org/en/content/articlelanding/2025/nj/d4nj04364b\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Journal of Chemistry","FirstCategoryId":"92","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2025/nj/d4nj04364b","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Biocompatible ionic liquid-based aqueous micellar formulation to enhance solubility, stability and controlled release of sparingly soluble drugs†
The development of a universal carrier for sparingly soluble drugs (SSDs) remains a challenge to achieve an effective delivery system. To address this issue, surface active ionic liquid (SAIL)-based micellar systems have emerged as a prominent drug delivery carrier to increase the solubility of SSDs due to their exceptional physico-chemical properties. Herein, we report a new micellar formulation (MF) for SSDs (e.g., naproxen, ibuprofen and rosuvastatin) comprising a biocompatible SAIL choline oleate ([Cho][Ole]). The solubility of naproxen, ibuprofen and rosuvastatin is 138, 237 and 158-fold greater, respectively, in the developed MF as compared to their solubility in water due to the presence of hydrogen-bonds, π–π interactions, and cation–π interactions between the drug and SAIL[Cho][Ole]. No indications of drug precipitation, color change, phase separation, or flocculation as well as no discernible change in the quantity of NAP were found indicating the exceptional stability of NAP-loaded MF. In vitro release studies of NAP-loaded MF were carried out using phosphate-buffered saline (PBS) with dialysis membranes, simulating the buffering conditions of physiological body fluids. This experiment showed a 50–60% burst release of NAP within the first 4 hours, with no substantial release after 12 hours, suggesting a sustained release of NAP. Furthermore, cytotoxicity studies of SAIL[Cho][Ole]-based MFs were conducted to evaluate the relative safety effect of the MF. The result was found that the LC50 of SAIL[Cho][Ole] was 73.33 μg mL−1 whereas that of the positive control was 0.159 μg mL−1, indicating the lower toxicity of SAIL[Cho][Ole]. These results clearly suggest that the SAIL[Cho][Ole]-based aqueous MFs represent a promising substitute to conventional surfactant-based MFs and can be used as a biocompatible carrier for SSDs as well as a valuable strategy for drug delivery systems at different therapeutic areas.